Drugs / Primovist
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03215355 | Aug 2017 → Aug 2018 | liver cancer | Slawa Cwajna | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Primovist | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03215355 ↗ |
| Modality | Diagnostic / imaging agent | “a liver specific contrast agent” NCT03215355 ↗ |
| Route | Intravenous | “administered intravenously” NCT03215355 ↗ |